Company Profile

Adgero Biopharmaceuticals Holdings Inc (AKA: Kintara Therapeutics, Inc)
Profile last edited on: 11/13/2023      CAGE: 7X0V5      UEI: DKFQRJXK7SD3

Business Identifier: Photodynamic therapy ("PDT") platform
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4365 US Highway 1 Suite 211
Princeton, NJ 08540
   (609) 917-9789
Location: Single
Congr. District: 12
County: Mercer

Public Profile

In June 2020, Adgero Biopharmaceuticals Holdings, Inc. was acquired by Delmar that - soon after - changed it name to Kintara Therapeutics trading on NASDAQ with new sysmbol "KTRA". A biopharmaceutical company, Adgera had been building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform holding promise as a localized cutaneous or visceral tumor treatment. Additionally, PDT has immune activating properties and has potential therapeutic utility in oncology as a combination therapy in conjunction with immunotherapies. It is also being investigated in the cardiovascular setting as treatment for hemodialysis access failure. Adgero's lead product candidate, REM-001 therapy, has been previously studied in four Phase 2/3 clinical trials in patients with cutaneous metastatic breast cancer (CMBC), who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and with an existing robust safety database of approximately 1,100 patients across multiple indications, Adgero is currently focused on advancing the REM-001 program to late stage pivotal testing.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 1 NIH $225,000
Project Title: Photodynamic Therapy to Prevent Arteriovenous Fistula Maturation Failure

Key People / Management

  Frank Pilkiewicz

  Steven Rychnovsky